Introduction: Certain fermented dairy milk products may have bene®cial effects on plasma cholesterol levels. However, a number of studies have produced con¯icting results as to whether dietary supplementation by a probiotic dairy product containing the bacteria culture Causido 1 reduces plasma cholesterol. Objective: To conduct a meta-analysis of intervention studies to evaluate the effect of the Causido 1 culture on plasma total cholesterol and low-density lipoprotein (LDL)-cholesterol. The probiotic milk product: The yoghurt product Gaio 1 is fermented with Causido 1 , composed of one strain of Enterococcus faecium (human species) with the proposed cholesterol-lowering effect, and two strains of Streptococcus thermophilus. Study inclusion and data extraction: Six studies were identi®ed from a literature search and from the yoghurt producer. All studies met the inclusion criteria. Summary data for plasma concentrations of total cholesterol and LDL-cholesterol were extracted from the original publications or by personal request to the authors. Data from 4 ± 8 weeks of treatment duration was used. Statistical analysis: We performed a traditional meta-analysis where mean differences between intervention and control of the pre ± post changes in total cholesterol and LDL-cholesterol were calculated, as well as 95% con®dence intervals (CIs). Results: In the six studies included in the meta-analysis, the Gaio 1 interventions produced changes in total cholesterol above those of the control groups ranging from À0.02 to À1.02 mmolal and in LDL-cholesterol ranging from À0.02 to À1.15 mmolal. After inclusion of an open-label study, the meta-analysis of the doubleblind studies showed that Gaio 1 as compared to the control group changed total cholesterol by À0.22 mmolal (95% CI: À0.35 to À0.08, P`0.01) and LDL-cholesterol by À0.20 mmolal (95% CI: À0.33 to À0.06, P`0.005). The outcome was essentially the same if all studies were included. Conclusions: The present meta-analysis of controlled short-term intervention studies shows that the fermented yoghurt product produced a 4% decrease in total cholesterol and a 5% decrease in LDL-cholesterol when the open-label study is excluded. To demonstrate sustained effects on blood lipids, long-term studies are required. Sponsorship: MD Foods AaS, Denmark. Descriptors: probiotic milk product; plasma cholesterol; meta-analysis
Introduction
Dietary efforts to reduce plasma low-density lipoprotein (LDL)-cholesterol play an important role in the prevention of ischaemic heart disease (IHD). The lactic acid bacteria's ability to reduce LDL-cholesterol has therefore gained increased attention in the recent decades. There are, however, con¯icting results of these milk products' ef®cacy to reduce plasma cholesterol. A number of studies have assessed whether an addition to the habitual diet of a fermented (probiotic) dairy product Gaio 1 , containing a bacterial culture Causido 1 , can reduce plasma cholesterol and other risk factors of IHD. Five studies showed a small bene®cial short-term effect of 6 ± 10% on LDL-cholesterol (Sarkisov et al, unpublished results, 1991; Agerbñk et al, 1995; Richelsen et al, 1996; Bertolami et al, 1999; Agerholm-Larsen et al, 2000) . However, the long-term effect was inconclusive (Richelsen et al, 1996) and one study failed to see any effect at all (Sessions et al, 1998) . In order to achieve a clearer picture, we performed a meta-analysis on the association between Gaio 1 intake and changes of total cholesterol and LDL-cholesterol levels.
The probiotic milk product
The tested bacteria culture Causido 1 comes from Ukraine, where the initial study was performed at Kiev University on the effects of the bacteria on plasma cholesterol. The clinical observations have, however, not been published in an international scienti®c journal (Sarkisov et al, unpublished data, 1991) . In general, it was decided that more strictly controlled clinical double-blinded trails were neces-sary to re-examine whether the product affected plasma cholesterol. After some product development, the Danish dairy corporation MD Foods AaS (Aarhus, Denmark) launched the fermented milk product Gaio 1 in Denmark in 1993. The product is fermented with Causido 1 , composed of one strain of Enterococcus faecium (human species) with the proposed cholesterol-lowering effect, and two strains of Streptococcus thermophilus. In all the studies included, Gaio 1 was presumably manufactured in the same way and contained the same dietary composition. We assume the same for the placebo yoghurt products. A 100 g sample of the test yoghurt is supposed to contain about 224 kJ (54 kcal), 5.4 g protein, 3.3 g carbohydrate and 1.7 g fat (1% milk fat and 0.7% rapeseed oil). The cholesterol content was 3 ± 4 mga100 g yoghurt. The placebo milk product was of identical composition to the test yoghurt, but chemically fermented with an organic acid (delta-acidlactone) instead of a living bacterial culture.
Inclusion and exclusion of studies
Knowledge of the initial study conducted in Kiev in 1991 using the Causido 1 culture and copies of the study's original unpublished data have been passed on to the authors through the yoghurt producer MD Foods AaS, Denmark. Based on this study, we performed a literature search for published papers covering the period January 1991 to December 1999. The predetermined inclusion criteria were limited to: (1) Causido 1 (bacteria culture in a yoghurt product called Gaio 1 ); (2) clinical intervention studies on humans with a control group; (3) publication in English language. The studies were identi®ed by a systematic search in Medline (National Library of Medicine, Silver Platter, Bethesda, MD), EMBASE and Science Citation Index. A total of three publications on the search term Causido 1 emerged and ful®lled the inclusion criteria (Agerbñk et al, 1995; Richelsen et al, 1996; Bertolami et al, 1999) . The fourth study was published in a book and was located via MD Foods AaS (Sessions et al, 1998) . The ®fth study was performed by our own group (AgerholmLarsen et al, 2000) . To ensure comparability, the included results were not adjusted for any variables. We also wanted to test whether the duration of the interventions had a signi®cant in¯uence on the outcome and performed an analysis including duration as a parameter. All six studies on Causido 1 are presented in Table 1 .
Data extraction
We aimed to analyse summary data (mean values + standard deviation) on total cholesterol and LDL-cholesterol. Differences before and after intervention with 95% con®dence intervals (CI) are presented as well. Whenever possible, we used data presented in the original paper. If mean values ( + standard deviation) of total cholesterol and LDL-cholesterol and changes compared to baseline were not available from the publication, personal requests to the authors provided the information.
In order to ensure comparability we did not adjust for any variables, although, for example, the study by Agerholm-Larsen et al (2000) showed a signi®cant decrease in LDL-cholesterol after adjustment for changes in body weight.
Due to differences in duration of the enrolled studies (4 ± 24 weeks), we chose to use the most comparable measurement points (nearest to 4 or 8 weeks). The study by Richelsen et al (1996) used several different time point measurements (weeks 4, 12 and 24). We used the week 4 measurement. In opposition to the week 24 data, the week 4 data showed a signi®cant effect on LDL cholesterol. Four of the six studies used a double-blind design with a placebo yoghurt. One study (Sarkisov et al, 1991) was an openlabel intervention where the control group did not receive a placebo yoghurt. One study, Bertolami et al, used a crossover design with three phases: phase 1, diet only; phase 2, diet placebo; and phase 3, diet Gaio 1 . In this study, we used phase 3Àphase 2 as the treatment measure, and phase 2Àphase 1 as the control measure. The data on changes in total cholesterol and LDL-cholesterol from the six studies included are presented in Table 2 . Week 4 data were used in the meta-analysis.
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Statistical analysis
The values used for the meta-analysis were the difference calculated in total cholesterol (Tcholdiff) and LDL-cholesterol (LDLdiff) as: (postÀpre) intervention À(postÀpre) control . In other words, the difference is the change in the intervention group (I) minus the change in the control group (C). The standard deviation of the difference in plasma cholesterol changes between groups I and C was estimated by standard equations from the reported standard error, standard deviations or 95% CIs of the changes within the groups and differences between the groups. Standard methods of meta-analysis (Normand, 1999) were used to carry out a chi-square test of homogeneity of study means, a ®xed effects estimate, standard error and test of the difference in cholesterol change between intervention and control treatment, and a random effects estimate and standard error. In either case, the studies are combined to obtain an overall estimate, with individual studies weighted according to their sample size and the variance of their estimated effects.
The study by Bertolami et al (1999) used a cross-over design but was treated in the analysis as if it was a parallel design. As it gives an overestimate of the standard deviation, resulting in a lower meta-analysis and regression weight for that study, this is conservative. Statistical analyses were made using SAS (SAS Institute Inc., SASa STAT Software: Changes and Enhancements through Release 6.12, Cary NC, 1997), with PROC MIXED in SAS used for the random effects analysis.
Results
In the meta-analysis including all six studies, Gaio 1 produced changes (IÀC) in total cholesterol ranging from À0.02 to À1.02 mmolal as compared to the control groups with negative values indicating decreases. The outcome of the meta-analysis for total cholesterol was that the Gaio 1 interventions as compared to the control groups produced a change in total cholesterol of À0.46 mmolal more (95% CI: Figure 1 Differences of the changes in total cholesterol (intervention minus control) (mmolal) with 95% CIs for the six studies included in the metaanalysis. The estimates of overall ®xed effects and random effects from the meta-analysis are also shown.
Effect of probiotic milk product L Agerholm-Larsen et al À0.57 to À0.35 mmolal; P`0.0001) in the ®xed effects analysis and À0.39 mmolal more (95% CI: À0.77 to À0.01 mmolal; P`0.05) in the random effects analysis. The test of homogeneity of study means gave Q 87.2 (d.f. 5, P`0.0001). This indicates heterogeneity of study means and a preference for the random effect analysis. Figure 1 shows these cholesterol changes and combined estimates along with 95% CIs. The changes in LDL-cholesterol ranged from À0.02 to À1.15 mmolal when all six studies were included. The meta-analysis for LDL-cholesterol showed that the Gaio 1 interventions as compared to the control groups produced an LDL-cholesterol change of À0.43 mmolal more (95% CI: À0.54 to À0.32 mmolal; P`0.0001) in the ®xed effects analysis and À0.39 mmolal more (95% CI: À0.82 to 0.04; P`0.07) in the random effects analysis. The test of homogeneity of study means gave Q 101.01 (d.f. 5, P`0.0001), again indicating heterogeneity and a preference for the random effects analysis. Figure 2 shows these LDL-cholesterol changes and combined estimates along with a 95% CI.
When considering the response of the meta-analysis visually, one study is obviously deviating from the others (Figures 1 and 2) . As a sensitivity check we re-analysed the data without this study (Sarkisov, 1991 , the only nonblinded study, and the control group did not receive an inert yoghurt). The outcome of this meta-analysis showed an estimated change in total cholesterol of À0.23 mmolal (95% CI: À0.41 to À0.05 mmolal; P`0.05) in the random effects analysis and a change of À0.22 mmolal (95% CI: À0.35 to À0.08 mmolal; P`0.01) in the ®xed effects analysis. The test of homogeneity of study means gave Q 7.22 (d.f. 4, P 0.88). When testing LDL-cholesterol, the outcome showed an estimated change of À0.25 mmolal (95% CI: À0.48 to À0.01 mmolal; P`0.05) in the random effects analysis and À0.20 mmolal (95% CI: À0.33 to À0.06 mmolal; P`0.05) in the ®xed effects analysis. The test of homogeneity of study means gave Q 8.88 (d.f. 4, P 0.94). When excluding Sarkisov's study, the Q statistic on both analyses became signi®cant, indicating homogeneity of studies and a preference for the ®xed effect model results.
We performed a regression analysis using study duration in the model (with and without the Sarkisov study) but the effect of duration was non-signi®cant (P b 0.2).
Discussion
This meta-analysis of the changes in total cholesterol and LDL-cholesterol made on a fermented yoghurt product in the six controlled intervention studies, involving 425 subjects of both genders and different initial cholesterol levels, shows that these cultures reduced both total and LDLcholesterol by about 6% and 9%, respectively, compared to the control group. A meta-analysis performed without the open-labelled Sarkisov study strengthens the statistical signi®cance of the conclusions as compared to the ®rst analysis, although the effects were numerically smaller in magnitude. After exclusion of the Sarkisov study there was homogeneity of variance between the studies, and this indicates that the ®xed effects model should be used. Changes of À0.22 mmolal in total cholesterol and of À0.20 mmolal in LDL-cholesterol were found in the ®xed effects model, which corresponds to a decrease of 4% and 5%, respectively.
The repetition of the meta-analysis excluding the openlabelled study by Sarkisov was justi®able because this study was the only non-double-blind study. In that study there was no yoghurt control group, and all subjects knew they were exposed to a yoghurt product with putative bene®cial effects. Therefore, a change in their habitual diet cannot be ruled out either. We believe these arguments and the heterogeneity of variance with the rest of the studies justify repeating the analyses excluding the Sarkisov study.
When we included study duration as a variable in the ®xed effect model, we found no duration effect with or without the variance weights and with or without the Sarkisov study. This means that no association between reduction in plasma cholesterol and duration of the study Figure 2 Differences of the changes in LDL-cholesterol (intervention minus control) (mmolal) with 95% CIs for the six studies included in the metaanalysis. The estimates of overall ®xed effects and random effects from the meta-analysis are also shown.
Effect of probiotic milk product L Agerholm-Larsen et al interventions was found with the range of these short-term studies. The study interventions are characterized by a heterogeneous group of subjects (Table 1 ). There are both male and female subjects with ages ranging from 18 to 80 y. There are only small differences in BMI (all normalweight, except for overweight subjects in Agerholm-Larsen et al, 2000) . The values of total cholesterol at baseline, which depends on age and gender, were also found to differ. There were also a small number of subjects enrolled in the individual study. These small sample sizes may have resulted in relatively lower statistical power for individual studies. When the studies are combined in a meta-analysis, weighted according to sample size and variance of estimated effect, the analysis seems to provide strong evidence for the short-term effect of the Causido 1 culture on plasma cholesterol lowering.
In certain studies, control of dietary compliance was included in the design by dietary interviews before and after intervention (Agerbñk et al, 1995; Richelsen et al, 1996) , dietary records before, during and after intervention (Agerholm-Larsen et al, 2000) , partial supervision during intake at department (Agerholm-Larsen et al, 2000) or clinical measurements (Agerholm-Larsen et al, 2000) . Intake of the same yoghurt volume over a long period of time (12 ± 24 weeks) will probably require a closely monitored intervention, because subjects may have a tendency to be less compliant to the product over a long period of time. Therefore, dietary compliance seems to be taken into consideration. The question is whether dietary compliance has an important in¯uence on the outcome of this metaanalysis and whether some of the study results are due to non-compliance. If this is the case, the outcome of the meta-analysis is an underestimation of the real effect on blood lipids. A compliance method measuring recovery of lithium in urine could probably be used in future studies for a more correct determination of dietary compliance.
The cholesterol lowering effect is suggested to be due to the Enterococcus faecium strain in the Causido 1 culture (Agerbñk et al, 1995) . A potential explanation for its mechanism is an association between gut micro¯ora and cholesterol absorption in the small intestine, based on Enterococcus faecium's ability to tolerate bile (Taranto et al, 1996) . The speci®c action of the strain is, however, still unclear.
The placebo yoghurts used in the interventions were free of Lactobacillus cultures. However, milk fermented with Streptococcus thermophilus would probably have been more appropriate in assessing the cholesterol-lowering properties of the Enterococcus faecium culture.
In the last decade, few human studies have been conducted on probiotics (De Roos & Katan, 2000) . Studies investigating probiotics' cholesterol-lowering effects have been particularly limited. The ®rst studies on Causido 1 by Agerbñk et al (1995) and Richelsen et al (1996) indicated that a short-term effect of Enterococcus faecium was detected but was inconclusive and that further studies were needed. Since De Roos and Katan's literature search, other studies on Causido 1 have been published. Two of these studies indicate a short-term cholesterollowering effect (Bertolami et al, 1999; Agerholm-Larsen et al, 2000) , while one study shows no differences (Sessions et al, 1998) . The two studies on Causido 1 with an intervention period longer than 12 ± 24 weeks have shown no bene®cial effects on LDL cholesterol (Richelsen et al, 1996; Sessions et al, 1998) . We cannot draw any conclusions from the present meta-analysis on the longer-term effect, and therefore further investigations are needed to clarify this point.
A meta-analysis may suffer from unpublished data material because negative studies often remain unpublished. This could lead to publication bias. We have, however, no knowledge of unpublished material on Causido 1 culture. Of the six studies used here, two even showed no association between intake of Causido 1 and a reduction in plasma cholesterol (Sessions et al, 1998; Richelsen et al, 1996) , while one study showed no effects when excluding the addition of adjustments for change in body weight (Agerholm-Larsen et al, 2000) . A 9% reduction of LDL-cholesterol was seen in the present metaanalysis based on all six studies. A 10% decrease in LDL-cholesterol would correspond to a decrease in the risk of IHD of 20 ± 30% and would therefore have bene®cial effects on the incidence and prevention of IHD (Law & Wald, 1994) . To achieve this bene®t, a sustained lowering is required. Further studies of longer duration and with strict compliance may provide more information about whether or not the decrease is a sustained effect.
In conclusion, the present meta-analysis based on ®ve controlled study interventions shows that the intake of a fermented yoghurt product produced a statistically signi®-cant and clinically important reduction in plasma cholesterol. We found a reduction of 5% in LDL-cholesterol, a reduction which is considered to have a bene®cial effect on risk factors for IHD. However, long-term studies on Causido 1 are required to document a sustained effect on the blood lipids.
